BORTEZOMIB, LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE REGIMEN FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND INTRODUCTION OF SERUM FREE LIGHT CHAINS (SFLC) IN RESPONSE MONITORING: PRELIMINARY DATA

被引：0
|
作者：
Pisani, F.
Cordone, I. [1 ]
Dessanti, M. L. [2 ]
Cigliana, G. [1 ]
Frollano, B. [1 ]
Masi, S. [1 ]
Mengarelli, A. [2 ]
Spadea, A. [2 ]
D'Andrea, M. [2 ]
Petti, M. C. [2 ]
机构：
[1] Ist Nazl Tumori Regina Elena, SC Patol Clin, Rome, Italy
[2] Ist Nazl Tumori Regina Elena, SC Ematol, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [41] LENALIDOMIDE COMBINED WITH LIPOSOMAL DOXORUBICIN AND LOW DOSE DEXAMETHASONE (RDD) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: SAFETY AND EFFICACY
    Pavone, V.
    Mele, A.
    De Risi, C.
    Rossini, B.
    Carlino, D.
    Sibilla, S.
    De Francesco, R.
    Greco, G.
    Fina, M.
    Ferrara, P.
    Morciano, M.
    Ostuni, A.
    Pavone, V.
    HAEMATOLOGICA, 2012, 97 : 602 - 603
  • [42] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    BLOOD, 2015, 126 (23)
  • [43] Bortezomib, doxorubicin and dexamethasone combination therapy followed by thalidomide and dexamethasone as a salvage treatment for relapsed multiple myeloma: Preliminary analysis of efficacy and safety
    Lee, S. S.
    Lee, J. H.
    Kim, B. S.
    Chung, J. S.
    Joo, Y. D.
    Ryoo, H. M.
    Do, Y. R.
    Jin, J. Y.
    Kang, H. J.
    Lee, K. W.
    Lee, M. H.
    Shim, H.
    Kim, K.
    Yoon, S. S.
    Suh, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 92 - 92
  • [44] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Yu, Jihnhee
    Ailawadhi, Sikander
    Sher, Taimur
    Mohr, Alice
    Bernstein, Zale P.
    Barcos, Maurice
    Patel, Mehul
    Iancu, Dan
    Lee, Kelvin
    Czuczman, Myron S.
    LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1096 - 1101
  • [45] Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma
    Murng, S. H. K.
    Follows, L.
    Whitfield, P.
    Snowden, J. A.
    Swallow, K.
    Green, K.
    Sargur, R.
    Egner, W.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 171 (02): : 201 - 209
  • [46] Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
    Waldschmidt, Johannes M.
    Keller, Alexander
    Ihorst, Gabriele
    Grishina, Olga
    Mueller, Stefan
    Wider, Dagmar
    Frey, Anna V.
    King, Kristina
    Simon, Roman
    May, Annette
    Tassone, Pierfrancesco
    Duyster, Justus
    Jung, Manfred
    Raje, Noopur
    Waesch, Ralph
    Engelhardt, Monika
    HAEMATOLOGICA, 2018, 103 (10) : E473 - E479
  • [47] A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)
    Berenson, James R.
    Yellin, Ori
    Cartmell, Alan D.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Nassir, Youram
    Vescio, Robert
    Swift, Regina A.
    BLOOD, 2010, 116 (21) : 1254 - 1255
  • [48] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Sung Sook Lee
    Cheolwon Suh
    Bong-Seog Kim
    Jooseop Chung
    Young-Don Joo
    Hun-Mo Ryoo
    Young Rok Do
    Jong-Youl Jin
    Hye Jin Kang
    Gyeong-Won Lee
    Moon Hee Lee
    Hyeok Shim
    Kihyun Kim
    Sung-Soo Yoon
    Soo Mee Bang
    Ho Young Kim
    Je-Jung Lee
    Jinny Park
    Dong Soon Lee
    Jae-Hoon Lee
    Annals of Hematology, 2010, 89 : 905 - 912
  • [49] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Lee, Sung Sook
    Suh, Cheolwon
    Kim, Bong-Seog
    Chung, Jooseop
    Joo, Young-Don
    Ryoo, Hun-Mo
    Do, Young Rok
    Jin, Jong-Youl
    Kang, Hye Jin
    Lee, Gyeong-Won
    Lee, Moon Hee
    Shim, Hyeok
    Kim, Kihyun
    Yoon, Sung-Soo
    Bang, Soo Mee
    Kim, Ho Young
    Lee, Je-Jung
    Park, Jinny
    Lee, Dong Soon
    Lee, Jae-Hoon
    ANNALS OF HEMATOLOGY, 2010, 89 (09) : 905 - 912
  • [50] SERUM-FREE LIGHT-CHAINS (SFLC) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING LIGHT-CHAIN MULTIPLE MYELOMA (LCMM)
    Anglada Fernandez, L. Lopez
    Cueto-Felqueroso, C.
    Mateos, M. V.
    Rosinol, L.
    Oriol, A.
    Teruel, A. I.
    Palomera, L.
    Arriba, F.
    Bargay, J. J.
    Hernandez, J. M.
    Gonzalez, Y.
    Maria Jesus, B.
    Valeri, A.
    Granell, M.
    Garcia Sanz, R.
    Lopez de la Guia, A.
    Besalduch, J.
    Martinez, R. B.
    Hernandez, M. T.
    Puerta, P.
    Blade, J.
    San Miguel, J.
    Lahuerta, J. J.
    Martinez-Lopez, J.
    HAEMATOLOGICA, 2017, 102 : 524 - 524
12345